A Study of KC1036 in Patients with Advanced Solid Tumors

A Phase I, Open-label, Dose Escalation Study Evaluating the Safety, Pharmacokinetics and Preliminary Efficacy of KC1036 in the Patients with Advanced Recurrent or Metastatic Solid Tumors

The purpose of this study is to evaluate the safety，tolerability, pharmacokinetics, and preliminary efficacy of KC1036 in participants with advanced recurrent or metastatic solid tumors. The trial will be divided into three parts: dose-escalation phase, dose-expansion phase, RP2D-extension phase.

Study Overview

• Status: Recruiting
• Conditions: Advanced Solid Tumors
• Intervention / Treatment: Drug: KC1036

• Study Type: Interventional
• Enrollment (Estimated): 207
• Phase: Phase 1

Contacts and Locations

Study Locations

• China
  • Chongqing
    • ChongQing, Chongqing, China
      • Recruiting
      • Chongqing University Cancer Hospital
      • Contact: Junyu Wu, Ph.D; Phone Number: 6803 0086-10-82898888; Email: wujy@konruns.cn
      • Contact: Weiqi Nian, ph.D
  • Hainan
    • Haikou, Hainan, China
      • Recruiting
      • The First Affiliated Hospital of Hainan Medical University
      • Contact: Junyu Wu, Ph.D; Phone Number: 6803 0086-10-82898888; Email: wujy@konruns.cn
      • Contact: xinbao Hao, ph.D
  • Sichuan
    • Chengdu, Sichuan, China
      • Recruiting
      • West China Hospital
      • Contact: Yongsheng Wang, Ph.D
      • Contact: Junyu Wu, Ph.D; Phone Number: 6803 0086-10-82898888; Email: wujy@konruns.cn
      • Contact: Qiu Li, Ph.D

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Histologically or cytologically confirmed recurrent or metastatic solid tumors;
• Patients who have failed standard or conventional treatment, Including chemotherapy, targeted therapy, immunotherapy:

Documented disease progression after, or refractory to, or intolerant of prior standard or established therapy known to provide clinical benefit for their condition; or documented disease progression within 24 weeks after prior adjuvant/neoadjuvant therapy;

• At least one measurable lesion (by RECIST 1.1);
• Eastern Cooperative Oncology Group performance status score of 0 or 1;
• Life expectancy > 12 weeks;
• Patients should participate in the study voluntarily and sign informed consent.

Exclusion Criteria:

• Untreated brain metastases or symptoms of brain metastases cannot be controlled more than 4 weeks;
• Other kinds of malignancies;
• Hematologic, renal, and hepatic function abnormities;
• Risk of bleeding;
• Gastrointestinal abnormalitiest;
• Cardiovascular and cerebrovascular diseases;
• Prior anti-tumor therapies with chemotherapy, radiotherapy, hormonotherapy, biotherapy, immunotherapy, operation within 4 weeks of enrollment;
• Presence of unresolved toxicities from prior anti-tumor therapy, defined as having not resolved to NCI CTCAE V5.0 grade 0 or 1 with the exception of alopecia;
• Involved in other clinical trials within 4 weeks of enrollment;
• Major surgical procedure, open biopsy, or significant traumatic injury 4 weeks days of enrollment;
• History of organ allograft;
• Need immunosuppressive agents or systemic or absorbable topical hormone therapy for immunosuppression;
• Uncontrolled ongoing or active infection;
• Known history of human immunodeficiency virus (HIV) infection or current chronic or active hepatitis B or C infection requiring treatment with antiviral therapy;
• Pregnant or lactating women or those who do not take contraceptives, including men;
• Suffering from mental and neurological diseases;
• Any other metabolic dysfunction, abnormal physical examination findings, or clinical laboratory findings;
• Inability to comply with protocol required procedures.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: KC1036; Patients take a single dose of KC1036 for the pharmacokinetic study, then off for 5 days before the first cycle begins. In the subsequent treatment cycles, KC1036 are given orally once daily, 21 days as a cycle.	Drug: KC1036; Part 1: Dose-escalation phase , KC1036 10mg~80mg, consists of 5 Cohorts. Part 2: Dose-expansion phase, consists of 3~4 Cohorts based on part 1. Part 3:RP2D-extension phase, Recommended dose of KC1036 based on part 1and part 2.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Maximum tolerated dose (MTD)	MTD will be defined as the maximum dose level at which no more than 1 of 3 participants experience a dose-limiting toxicity (DLT) within the first 4 weeks of multiple dosing.	First 4 weeks after initial administration of KC1036
Adverse events (AEs)	Incidence of treatment-related AEs	From enrollment up to 30 days after last dose

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Pharmacokinetics (PK) profile: Cmax	Peak Plasma Concentration	First 4 weeks after initial administration of KC1036
Pharmacokinetics (PK) profile: Tmax	Time to reach the maximum plasma concentration	First 4 weeks after initial administration of KC1036
Pharmacokinetics (PK) profile: T1/2	Terminal half-life	First 4 weeks after initial administration of KC1036
Pharmacokinetics (PK) profile: AUC0-t and AUC0-∞	Area under the single-dose plasma concentration-time curve from Hour 0 to the last quantifiable measurable plasma concentration, or Area under the single-dose plasma concentration-time curve from Hour 0 to infinity	First 4 weeks after initial administration of KC1036
Objective Response Rate (ORR)	Overall response rate (ORR) was defined as the percentage of participants with a best overall complete response (CR) or partial response (PR) per RECIST 1.1.	Every 6 weeks for the duration of study participation; estimated to be 12 months
Progression-free survival (PFS)	Progression-free survival (PFS) was defined as the time from the start date of study drug to the date of the first radiologically documented progressive disease (PD) per RECIST 1.1 or death due to any cause.	Every 6 weeks for the duration of study participation; estimated to be 12 months
Disease Control Rate (DCR)	Disease Control Rate (DCR) was defined as the percentage of participants with a best overall complete response (CR), partial response (PR), or stable disease (SD) per RECIST 1.1.	Every 6 weeks for the duration of study participation; estimated to be 12 months
Duration of Response (DOR)	Duration of response (DOR) was defined as the time from first documented response (partial response (PR) or complete response (CR)) to the date of first documented disease progression (PD) or death due to any cause, among patients with a confirmed PR or CR per RECIST 1.1.	Every 6 weeks for the duration of study participation; estimated to be 12 months
Overall Survival (OS)	Overall Survival (OS) was defined as the time from the start date of study drug to the date of death due to any cause.	From the first medication to death due to any cause; estimated to be the subject's death, loss to follow-up, or end of the study]

Collaborators and Investigators

• Sponsor: Beijing Konruns Pharmaceutical Co., Ltd.

Study record dates

Study Major Dates

• Study Start (Actual): September 4, 2020
• Primary Completion (Estimated): October 31, 2025
• Study Completion (Estimated): December 31, 2025

Study Registration Dates

• First Submitted: May 11, 2020
• First Submitted That Met QC Criteria: May 11, 2020
• First Posted (Actual): May 14, 2020

Study Record Updates

• Last Update Posted (Actual): October 17, 2024
• Last Update Submitted That Met QC Criteria: October 15, 2024
• Last Verified: October 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms
• Other Study ID Numbers: KC1036-I-01

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No